(Q42926215)

11 November 2017

title

Potential economic impact of increasing low dose aspirin usage on CVD in the US (English)

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

23 June 2024

1 reference

Agnes Benedict

2

1 reference

11 November 2017

Feng Pan

3

1 reference

11 November 2017

Stephanie C. Manson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20738228

23 June 2024

Kim U. Wittrup-Jensen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20738228

23 June 2024

A. Mark Fendrick

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20738228

23 June 2024

language of work or name

English

0 references

publication date

1 October 2010

1 reference

full work available at URL

11 November 2017

http://www.tandfonline.com/doi/pdf/10.1185/03007995.2010.514481

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Current Medical Research and Opinion

23 June 2024

published in

1 reference

11 November 2017

volume

26

1 reference

11 November 2017

issue

10

1 reference

11 November 2017

page(s)

2365-2373

1 reference

Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis

11 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

An Update on Aspirin in the Primary Prevention of Cardiovascular Disease

23 June 2024

2

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

23 June 2024

3

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke

23 June 2024

5

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

23 June 2024

6

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System

23 June 2024

7

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin use among adults aged 40 and older in the United States: results of a national survey

23 June 2024

8

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

23 June 2024

9

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

23 June 2024

10

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis

23 June 2024

11

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation

23 June 2024

12

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease

23 June 2024

13

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan

23 June 2024

14

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis

23 June 2024

15

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk

23 June 2024

16

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis

23 June 2024

17

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

23 June 2024

18

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Primary and subsequent coronary risk appraisal: New results from the Framingham study

23 June 2024

19

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Probability of stroke: a risk profile from the Framingham Study

23 June 2024

20

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Cardiovascular disease risk profiles.

23 June 2024

21

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

23 June 2024

22

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease

23 June 2024

23

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention

23 June 2024

24

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?

23 June 2024

25

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications

23 June 2024

26

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses

23 June 2024

27

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials

23 June 2024

28

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Institutionalization after stroke.

23 June 2024

30

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

23 June 2024

32

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Predictive variables for mortality after acute ischemic stroke

23 June 2024

34

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Impact of Sex on Long-term Mortality From Acute Myocardial Infarction vs Unstable Angina

23 June 2024

35

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Long-Term Disability After First-Ever Stroke and Related Prognostic Factors in the Perth Community Stroke Study, 1989–1990

23 June 2024

36

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement

23 June 2024

37

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

23 June 2024

38

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators

23 June 2024

40

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort.

23 June 2024

41

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Geographic variations in stroke incidence and mortality among older populations in four US communities

23 June 2024

42

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

23 June 2024

43

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

Aspirin for primary prevention of cardiovascular events.

23 June 2024

44

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.514481

23 June 2024

Identifiers

1 reference

11 November 2017

1 reference